Table 3Mayrand et al8: Expected False Positives, Colposcopies, CIN2-3 Cases, Cancer Cases, and Cancer Deaths Associated With Cytology and HPV Test-Based Strategies, Either Alone or in Combination*

StrategyFalse PositivesColposcopiesCIN2-3 CasesCancer CasesCancer Deaths
Cytology, q3, age 21;
Cytology and HPV, q5, age 30
117.70323.0086.367.741.42
Cytology, q5, age 21100.94274.0166.9313.152.81
Cytology, q3; age 21;
Cytology and HPV, q3, age 30
175.67446.3896.535.020.79
Cytology, q3, age 21165.52416.4482.618.971.65
Cytology, q2, age 21;
Cytology and HPV, q3, age 30
252.91600.9099.353.940.57
Cytology, q2, age 21244.38580.5891.716.240.99
Cytology, q1, age 21;
Cytology and HPV, q3, age 30
348.59790.56101.932.820.38
Cytology, q1, age 21464.751024.4299.892.790.36
*

Per 1,000 women. Time horizon is a lifetime. Age at which to begin screening is fixed at 21 years. For the combined cytology and HPV testing strategies, cytology-based screening is assumed before age 30 years, with a repeat cytology test for ASC-US results. The strategy of cytology and HPV testing begins at age 30 years. Women with normal cytology results and HPV negative results are assumed to be screened every 3 or 5 years.

Per 1,000 women. Time horizon is a lifetime. Age at which to begin screening is fixed at 21 years. For the combined cytology and HPV testing strategies, cytology-based screening is assumed before age 30 years, with a repeat cytology test for ASC-US results. The strategy of cytology and HPV testing begins at age 30 years. Women with normal cytology results and HPV negative results are assumed to be screened every 3 or 5 years.

From: Addendum

Cover of Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 86s.
Kulasingam SL, Havrilesky L, Ghebre R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.